These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2051559)

  • 1. Successful high-dose calcium treatment of aluminum-induced metabolic bone disease in long-term home parenteral nutrition.
    Lidor C; Schwartz I; Freund U; Gazit D
    JPEN J Parenter Enteral Nutr; 1991; 15(2):202-6. PubMed ID: 2051559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocalcemia complicating deferoxamine therapy in an infant with parenteral nutrition-associated aluminum overload: evidence for a role of aluminum in the bone disease of infants.
    Klein GL; Snodgrass WR; Griffin MP; Miller NL; Alfrey AC
    J Pediatr Gastroenterol Nutr; 1989 Oct; 9(3):400-3. PubMed ID: 2515268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term parenteral nutrition and metabolic bone disease.
    Hurley DL; McMahon MM
    Endocrinol Metab Clin North Am; 1990 Mar; 19(1):113-31. PubMed ID: 2113469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High bone turnover associated with an aluminum-induced impairment of bone mineralization.
    Charhon SA; Chavassieux PM; Chapuy MC; Traeger J; Meunier PJ
    Bone; 1986; 7(5):319-24. PubMed ID: 3790372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifactorial low remodeling bone disease during cyclic total parenteral nutrition.
    de Vernejoul MC; Messing B; Modrowski D; Bielakoff J; Buisine A; Miravet L
    J Clin Endocrinol Metab; 1985 Jan; 60(1):109-13. PubMed ID: 3917265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition.
    Ott SM; Maloney NA; Klein GL; Alfrey AC; Ament ME; Coburn JW; Sherrard DJ
    Ann Intern Med; 1983 Jun; 98(6):910-4. PubMed ID: 6407375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aluminum-related osteomalacia: clinical and histological improvement following treatment with desferrioxamine (DFO).
    Rapoport J; Chaimovitz C; Abulfil A; Mostovlavsky M; Gazit D; Bab I
    Isr J Med Sci; 1987 Dec; 23(12):1242-6. PubMed ID: 3440748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcitonin treatment of metabolic bone disease induced by parenteral nutrition].
    Wasmuth HH; Verhage CC
    Tidsskr Nor Laegeforen; 1993 Jun; 113(16):1987-9. PubMed ID: 8322348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteomalacia and aplastic bone disease in aluminum-related osteodystrophy.
    Andress DL; Maloney NA; Coburn JW; Endres DB; Sherrard DJ
    J Clin Endocrinol Metab; 1987 Jul; 65(1):11-6. PubMed ID: 3584392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferoxamine therapy of bone aluminum accumulation in renal dialysis patients.
    Nutr Rev; 1985 Apr; 43(4):103-5. PubMed ID: 3923410
    [No Abstract]   [Full Text] [Related]  

  • 13. Biliary excretion of aluminum in aluminum osteodystrophy with liver disease.
    Williams JW; Vera SR; Peters TG; Luther RW; Bhattacharya S; Spears H; Graham A; Pitcock JA; Crawford AJ; Palmieri GM
    Ann Intern Med; 1986 Jun; 104(6):782-5. PubMed ID: 3706930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of iron and aluminum related osteomalacia in a long-term hemodialysis patient].
    Yamagata K; Kobayashi M; Koyama A; Narita M; Amagai H; Ohno A; Yoshikawa S
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):437-42. PubMed ID: 1875564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of etidronate-mediated suppression of bone remodeling on aluminum-induced de novo bone formation.
    Quarles LD; Drezner MK
    Endocrinology; 1992 Jul; 131(1):122-6. PubMed ID: 1611990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated accumulation of aluminum by osteoid matrix in vitamin D deficiency. An animal model of aluminum toxicity.
    Hodsman AB; Anderson C; Leung FY
    Miner Electrolyte Metab; 1984; 10(5):309-15. PubMed ID: 6493159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferoxamine test and bone disease in dialysis patients with mild aluminum accumulation.
    de Vernejoul MC; Marchais S; London G; Bielakoff J; Chappuis P; Morieux C; Llach F
    Am J Kidney Dis; 1989 Aug; 14(2):124-30. PubMed ID: 2757018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic bone disease in adults receiving long-term parenteral nutrition: longitudinal study with regional densitometry and bone biopsy.
    Saitta JC; Ott SM; Sherrard DJ; Walden CE; Lipkin EW
    JPEN J Parenter Enteral Nutr; 1993; 17(3):214-9. PubMed ID: 8505825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.